DYAI DYADIC INTERNATIONAL INC
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1213809 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-7.6%
TTM net income YoY4.7%
TTM EPS YoY13.0%
Revenue 3-yr CAGR1.5%
Net income 3-yr CAGR—
Margins
Gross margin17.9%
Operating margin-236.7%
Net margin-226.9%
FCF margin—
EBITDA margin—
Returns
ROE-47,256.0%
ROA-71.4%
ROIC (approx.)—
Asset turnover0.31x
Leverage & solvency
Liabilities / assets132.5%
Debt / equity—
Current ratio1.69x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.00x
Accruals ratio0.3%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $449,101 | $961,138 | $1.11M | $565,526 | $1.16M | $966,630 | $393,572 | $817,376 |
| Cost of revenue | $375,115 | $984,165 | $791,840 | $384,608 | $1.02M | $613,591 | $297,658 | $352,819 |
| Gross profit | $73,986 | -$23,027 | $319,116 | $180,918 | $140,614 | $353,039 | $95,914 | $464,557 |
| R&D expense | $429,945 | $332,621 | $476,069 | $458,436 | $571,872 | $629,379 | $494,979 | $545,660 |
| SG&A expense | $1.45M | $1.69M | $1.76M | $1.25M | $1.48M | $1.44M | $1.60M | $1.44M |
| Operating income | -$1.81M | -$2.05M | -$1.90M | -$1.54M | -$1.93M | -$1.73M | -$2.00M | -$1.53M |
| Income tax | $0 | $0 | $0 | — | — | — | — | — |
| Net income | -$1.36M | -$2.12M | -$1.95M | -$1.57M | -$1.98M | -$1.79M | -$2.03M | -$1.55M |
| EPS (basic) | -0.04 | -0.06 | -0.05 | — | -0.06 | -0.06 | -0.07 | — |
| EPS (diluted) | -0.04 | -0.06 | -0.05 | — | -0.06 | -0.06 | -0.07 | — |
| Weighted avg. shares (diluted) | 38.29M | 36.44M | 36.40M | — | 34.08M | 30.10M | 29.89M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $3.93M | $1.43M | $4.25M | $4.62M | $5.83M | $2.14M | $5.06M | $6.51M |
| Short-term investments | $646,987 | $1.69M | $1.36M | $2.70M | $3.10M | $2.84M | $2.31M | $2.76M |
| Receivables | $1.52M | $1.30M | $996,464 | $1.09M | $916,574 | $715,317 | $221,719 | $237,027 |
| Current assets | $7.87M | $6.41M | $7.70M | $9.90M | $11.55M | $7.41M | $7.81M | $9.83M |
| Total assets | $7.93M | $6.54M | $7.81M | $9.95M | $11.67M | $8.14M | $7.89M | $9.93M |
| Current liabilities | $4.65M | $3.88M | $3.18M | $3.69M | $4.05M | $3.66M | $1.96M | $2.45M |
| Total liabilities | $10.51M | $8.92M | $8.22M | $8.71M | $9.07M | $8.67M | $6.97M | $7.46M |
| Shareholders' equity | -$2.58M | -$2.39M | -$407,732 | $1.23M | $2.61M | -$529,701 | $923,611 | $2.47M |
| Shares outstanding | 40.09M | 36.44M | 36.44M | 36.19M | 36.19M | 30.14M | — | 29.84M |
| Cash flow statement | ||||||||
| Operating cash flow | -$1.48M | -$1.82M | -$1.96M | -$1.77M | -$1.85M | -$130,015 | -$1.95M | -$696,395 |
| Investing cash flow | $1.15M | -$356,884 | $1.27M | $468,159 | $93,442 | -$961,620 | $482,104 | $1.26M |
| Financing cash flow | — | — | — | -$1 | $4.94M | $0 | $24,249 | $24,251 |
| Stock-based compensation | $141,829 | $144,372 | $139,299 | $192,339 | $172,352 | $340,462 | $225,030 | $274,808 |
Free plan shows the latest 8 periods; Pro shows all 35 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.